We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ROSN:RUSRosneft Analysis

Data as of 2026-07-29 - not real-time

$0.02

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Rosinbomb (ROSN) is trading at $0.0158, well below its 20‑day SMA of $0.01413 and far beneath the 50‑day ($0.01515) and 200‑day ($0.01842) averages, indicating a persistent bearish bias. The RSI sits at 55.3, suggesting neutral momentum, while the MACD histogram is positive and the signal line is bullish, offering a modest technical upside that is quickly eroded by decreasing volume and a clear bearish trend direction. The price is comfortably above the identified support level of $0.0091 but still under the resistance at $0.0177, leaving limited room for a sustainable rally. Volatility is extreme at 170% over the past 30 days, and a beta of 1.32 signals heightened sensitivity to market swings, compounded by a tiny market cap of roughly $7.2 million and low average trading volumes. The sector—Specialty Industrial Machinery—carries medium inherent risk, yet there are no evident regulatory headwinds for a U.S.‑based manufacturer of extraction presses. With zero reported revenue, earnings, cash, or debt, the company lacks any fundamental foothold, and the absence of dividend history confirms no income return for shareholders. Coupled with an “Extreme Greed” market sentiment index, the stock appears to be a speculative play driven more by market mood than intrinsic value.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below all major SMAs indicating bearish pressure
  • Decreasing volume eroding momentum
  • Extreme short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • MACD bullish crossover offering limited upside
  • Support level provides a floor but no earnings foundation
  • Market sentiment skewed toward speculative greed

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Zero revenue and earnings leave no long‑term growth path
  • High beta and volatility amplify downside risk
  • Lack of cash flow and dividend eliminates income potential

Key Metrics & Analysis

Financial Health

Industry P/E31.3

Technical Analysis

TrendBearish
RSI55.3
Support$0.01
Resistance$0.02
MA 20$0.01
MA 50$0.02
MA 200$0.02
MACDBullish
VolumeDecreasing
Fear & Greed Index88.91

Valuation

GradeUndervalued
TypeValue

Risk Assessment

Beta1.32
Volatility170.48%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.